Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Depreciation and Depletion (2020 - 2025)

Neuroone Medical Technologies' Depreciation and Depletion history spans 6 years, with the latest figure at $59945.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 0.67% year-over-year to $59945.0; the TTM value through Dec 2025 reached $239760.0, up 3.82%, while the annual FY2025 figure was $239363.0, 6.63% up from the prior year.
  • Depreciation and Depletion reached $59945.0 in Q4 2025 per NMTC's latest filing, up from $58745.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $61015.0 in Q2 2025 to a low of $13715.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $42115.8, with a median of $52229.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 104.47% in 2023, then increased 0.34% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $19582.0 in 2021, then surged by 54.79% to $30310.0 in 2022, then surged by 75.12% to $53078.0 in 2023, then grew by 12.19% to $59548.0 in 2024, then rose by 0.67% to $59945.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Depreciation and Depletion are $59945.0 (Q4 2025), $58745.0 (Q3 2025), and $61015.0 (Q2 2025).